TB-500 and thymosin beta-4 are listed as synonyms by most of the market. They are related but not identical, and the difference is the kind of thing a mass spectrometry result will settle immediately.
Thymosin beta-4
Thymosin beta-4 is a naturally occurring 43-residue protein, one of the most abundant intracellular proteins in many cell types. Its principal characterised function is binding monomeric actin, acting as a sequestering protein in the regulation of the actin cytoskeleton. Cell motility and cytoskeletal remodelling are the processes it is studied in.
TB-500
TB-500 is a designation attached to a synthetic fragment rather than the full-length protein. The region of interest is the actin-binding domain, a short motif within the parent sequence, and material sold as TB-500 is usually a fragment containing that domain rather than the complete 43 residues.
The practical point is that a 43-residue protein and a short fragment have different molecular weights, different synthesis costs and different analytical signatures. They are not substitutes on a mass basis, and the price difference between them is substantial for exactly that reason.
| Thymosin beta-4 | TB-500 | |
|---|---|---|
| What it is | A naturally occurring 43-residue protein | A designation for a synthetic fragment |
| Length | Full-length sequence | A short motif from within it |
| Region | The whole protein | The actin-binding domain |
| Mass | Substantially higher | Substantially lower |
| How to tell them apart | Mass spectrometry settles it in one result | Same |
| What a label alone proves | Nothing, the names are used loosely | Nothing |
Sold as synonyms, related but not identical. A mass result separates them immediately.
Why the naming is loose
The two names became interchangeable commercially rather than scientifically. Because catalogs list them as synonyms, a buyer ordering thymosin beta-4 may receive a fragment, and a buyer ordering TB-500 may receive something described either way.
There is one check that resolves it and it is already on a complete certificate: the observed mass. The full protein and a short fragment differ by several thousand daltons, which is not a subtle distinction. If a certificate reports a mass, the question is answered.
Catalog variants
Fragment designations appear in several forms, including combination products pairing a BPC-157 fragment with a TB-500 fragment in one vial. For any blend, the questions from the single-compound case multiply: what the ratio is, whether each component was assayed separately, and what the stated total mass refers to.
What to confirm
- The observed mass, against the theoretical mass for whichever species the supplier claims to be shipping.
- The sequence or fragment designation, stated explicitly rather than by trade name alone.
- Net peptide content, for the usual counterion and moisture reasons.
- For blends, whether purity is reported per component or only for the mixture.
Published work on thymosin beta-4 is preclinical and centres on actin regulation, cell migration and tissue-repair models. Material is supplied for laboratory research only.
What to ask a supplier about this pair specifically
Ask which of the two they are selling, in mass terms rather than by name. The full-length protein and the shorter synthetic fragment differ substantially in mass, so a single number answers the question that a label cannot.
Then ask what the certificate reports for identity. A mass consistent with the fragment, on a product sold under the full-length name, is not necessarily mislabelling, but it is a discrepancy worth having explained in writing before the order rather than afterwards.
Why the naming confusion persists
Because both names entered circulation through different routes and neither is a registered designation with a single controlled meaning. The market uses them interchangeably, suppliers inherit that usage, and the label ends up describing a category rather than a molecule.
That is a general problem in this catalogue rather than a quirk of one product, and it is the reason identity testing carries so much weight here. Counterfeit and mislabelled material covers what to check when a name and a number disagree.
Why this matters more than a naming quibble
Because the two materials differ substantially in mass, in length and in what a certificate can establish about them. Buying one while believing you bought the other is not a labelling inconvenience, it is a different molecule in the vial, and every downstream calculation inherits the error.
It also affects comparability. Published work describing the full-length protein is not describing the fragment, so a literature-based expectation formed from one and applied to the other has no basis. That is a general hazard with fragment designations and it is unusually pronounced here.
What a complete answer from a supplier looks like
A stated sequence or fragment range, a calculated mass that follows from it, and a certificate whose observed mass agrees. A supplier able to give all three is describing a specific material. One who answers only with a product name is describing a listing.
Where the answer is incomplete, independent identity testing settles it directly and an accredited laboratory will accept a single sealed vial. Third-party testing and ISO/IEC 17025 covers what that accreditation means.
What to record once you have established which you have
The name as the supplier uses it, the sequence or fragment range they state, the certificate mass, and the lot. Those four together let anyone reading the record later establish which of the two materials was used, which a product name alone will not do.
A practical closing note. Where a supplier cannot state which of the two they hold, that is itself the answer to the purchasing question, because a supplier who cannot describe their material in mass terms cannot support any claim made about it.
For where this sits among the other molecules a catalogue carries, not everything in a peptide catalog is a peptide covers how the classes differ.